SCHEMBL1648419

SCHEMBL1648419

O=CCCc1ccccc1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 3/20 0.61
ALDH1A1 P00352 5/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.47
HMGB1 P09429 2/20 0.43
PTPN1 P18031 1/20 0.43
TP53 P04637 1/20 0.42
HTT P42858 1/20 0.42
SLC16A3 O15427 3/20 0.42
KDM4E B2RXH2 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
HPGD P15428 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA7 P43166 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CA9 Q16790 1/20 0.42
NAPRT Q6XQN6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL70392 0.83 FOLH1 (0.76) FOLH1ALDH1A1ALOX15TSHRHMGB1
SCHEMBL30365583 0.83 FOLH1 (0.76) FOLH1ALDH1A1ALOX15TSHRHMGB1
SCHEMBL27924016 0.83 KDM4E (0.44) FOLH1ALDH1A1TSHRKDM4EHPGD
SCHEMBL4430320 0.83 FOLH1 (0.59) FOLH1ALDH1A1ALOX15TSHRHMGB1
SCHEMBL7253941 0.81 CLCN2 (0.45) FOLH1ALDH1A1ALOX15HMGB1PTPN1
SCHEMBL13477549 0.80 FOLH1 (0.56) FOLH1ALDH1A1ALOX15TSHRHMGB1
SCHEMBL22230549 0.80 FOLH1 (0.56) FOLH1ALDH1A1ALOX15TSHRPTPN1
SCHEMBL9717363 0.80 FOLH1 (0.40) FOLH1ALDH1A1TSHRMAPTTDP1
SCHEMBL1074384 0.80 FOLH1 (0.55) FOLH1ALDH1A1ALOX15TSHRHMGB1
SCHEMBL7071110 0.80 FOLH1 (0.66) FOLH1ALDH1A1ALOX15TSHRHMGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2505576-B1 CYCLIC COMPOUND, PROCESS FOR PRODUCTION THEREOF, RADIATION-SENSITIVE COMPOSITION, AND RESIST PATTERN FORMATION METHOD MITSUBISHI GAS CHEMICAL CO (JP) 2019-04-24 EP disclosed
US-8969629-B2 Cyclic compound, production process thereof, radiation-sensitive composition and resist pattern formation method MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2015-03-03 US disclosed
US-20120282546-A1 CYCLIC COMPOUND, PRODUCTION PROCESS THEREOF, RADIATION-SENSITIVE COMPOSITION AND RESIST PATTERN FORMATION METHOD MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2012-11-08 US disclosed
EP-2505576-A1 CYCLIC COMPOUND, PROCESS FOR PRODUCTION THEREOF, RADIATION-SENSITIVE COMPOSITION, AND RESIST PATTERN FORMATION METHOD Mitsubishi Gas Chemical Company, Inc. (JP) 2012-10-03 EP disclosed
WO-2011047981-A1 USE OF A DIALKYLPHENYL-4-AMINOPIPERIDINE AS AGENT FOR THE TREATMENT OF HUMAN PERSPIRATION; NOVEL COMPOUNDS AND COMPOSITIONS COMPRISING THEM L'OREAL (FR) 2011-04-28 WO disclosed
US-5856322-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS MERCK FROSST CANADA, INC. (CA) 1999-01-05 US disclosed
EP-0480717-B1 Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists MERCK FROSST CANADA INC (CA) 1998-04-15 EP disclosed
US-5565473-A USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS; MONTELUKAST AND ITS SODIUM SALT MERCK FROSST CANADA, INC. (CA) 1996-10-15 US disclosed
EP-0480708-B1 Hydroxyalkylquinoline ether acids as leukotriene antagonists MERCK FROSST CANADA INC (CA) 1995-10-11 EP disclosed
US-5270324-A Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists MERCK FROSST CANADA, INC. (CA) 1993-12-14 US disclosed
US-5266568-A Hydroxyalkylquinoline ether acids as leukotriene antagonists MERCK FROSST CANADA, INC. (CA) 1993-11-30 US disclosed
EP-0480708-A2 Hydroxyalkylquinoline ether acids as leukotriene antagonists MERCK FROSST CANADA INC. (CA) 1992-04-15 EP disclosed
EP-0480717-A1 Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists MERCK FROSST CANADA INC. (CA) 1992-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120282546-A1 CYCLIC COMPOUND, PRODUCTION PROCESS THEREOF, RADIATION-SENSITIVE COMPOSITION AND RESIST PATTERN FORMATION METHOD CROCC, XRCC6, CHEK1 FOLH1 4047/4885ALDH1A1 4268/4885ALOX15 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.